[Preclinical toxicological study of the new enterosorbent noolit].
The safety of the new enterosorbent noolit has been evaluated within the framework of its preclinical characterization. Single introduction of noolit to rats and mice (females and males) in maximum doses for intragastric administration (5.0 - 20.0 g/kg) does not lead to the loss of experimental animals. Single administration of large doses (5 - 40 times the effective dose) can reduce the growth of the total body weight and lead to the development of nonlethal pathological changes of hemopoietic organs, which is manifested by a weak regenerative anemia (5% of cases); neutrophile, eosinophile, and basophile leukocytosis (3% of cases); and a decrease in the glucose level in blood serum. In chronic experiments on rabbits, the administration of noolit for 3 months in a dose of 0.5 and 2.0 g/kg (2 and 8 times that recommended for humans) did not reveal any toxic action on the functional and morphological state of the main systems and organs (blood, liver, kidneys, lungs, heart, gastrointestinal tract, sex organs, etc.).
Karpova
G V
GV
Borodin
Iu I
IuI
Rachkovskaia
L N
LN
Fomina
T I
TI
Vetoshkina
T V
TV
Abramova
E V
EV
Novoselova
T I
TI
D000537:Aluminum Oxide / Q000494:pharmacology* / Q000633:toxicity; D000740:Anemia / Q000139:chemically induced; D000818:Animals; D001773:Blood Cells / Q000187:drug effects; D001786:Blood Glucose / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D016061:Enterosorption; D005260:Female; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D018020:Lithium Compounds / Q000494:pharmacology* / Q000633:toxicity; D008297:Male; D051379:Mice; D017646:Organosilicon Compounds / Q000494:pharmacology* / Q000633:toxicity; D011817:Rabbits; D051381:Rats; D013997:Time Factors
D001786:Blood Glucose; D018020:Lithium Compounds; D017646:Organosilicon Compounds; D000537:Aluminum Oxide